• Creo Medical Group published its 2025 annual report, highlighting faster commercial traction as its core endoscopy franchise expanded across procedures and regions.
• Portfolio broadened with 2025 launches of Speedboat Notch, SpydrBlade Flex, MicroBlate Flex, MicroBlate Fine, supporting deeper account penetration.
• Strategic reshaping continued via the sale of a 51% stake in Creo Medical Europe, shifting EMEA toward a more distributor-led model.
• Operating model moved further toward outsourcing, including post-period disposal and outsourcing of manufacturing to lower capital intensity.
• Management outlined additional funding actions, including steps toward a GBP 2 million convertible loan note, alongside plans for further equity funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creo Medical Group plc published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.